mAbxience, a Fresenius Kabi majority-owned biosimilar developer, has announced two strategic licensing agreements that will expand access to biosimilar therapies across Italy and Southeast Europe. The partnerships with Abiogen Pharma and Corapharm represent significant steps in the company's strategy to provide affordable, life-saving therapies worldwide.
Italian Market Partnership
Under the agreement with Abiogen Pharma announced on May 26, 2025, mAbxience will retain marketing authorization for the biosimilar candidate while Abiogen Pharma assumes responsibility for all commercialization and marketing activities in Italy. This collaboration leverages mAbxience's expertise in biosimilar development alongside Abiogen Pharma's established presence and commercial capabilities in the Italian pharmaceutical market.
"We are thrilled to partner with Abiogen Pharma to bring this biosimilar candidate to patients in Italy. Our collaboration reflects mAbxience's commitment to delivering high-quality, accessible therapies across various geographies," said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience.
Prisca Di Martino, Chief Commercial Officer at Abiogen Pharma, emphasized the strategic nature of the partnership: "This agreement is part of a broader, long-term strategic path for us. It reflects our dedication to therapeutic areas where we bring deep expertise. Partnering with mAbxience supports our goal to expand access to advanced biologic therapies in Italy."
Southeast European Expansion
The second agreement, announced on June 2, 2025, establishes a partnership with Corapharm to develop and commercialize a biosimilar candidate across multiple Southeast European markets. The territorial arrangement divides marketing authorization responsibilities, with mAbxience holding authorization in Croatia and Slovenia, while Corapharm assumes this role across Serbia, Bosnia and Herzegovina, North Macedonia, Montenegro, Kosovo, and Albania.
Corapharm will lead commercialization efforts throughout all these territories, while mAbxience oversees product development and manufacturing at its state-of-the-art facilities. This structure capitalizes on Corapharm's specialized knowledge of West Balkans territories and its established network in the region.
"We are excited to partner with Corapharm to bring this biosimilar candidate to patients across Southeast Europe," Millán noted, highlighting the geographic expansion of mAbxience's accessibility mission.
Miroslav Roca, CEO of Corapharm, expressed optimism about the collaboration: "Building on our successful track record in the pharmaceutical industry, we look forward to working with mAbxience to improve patient outcomes and expand access to critical treatments in these countries. Together, we remain dedicated to enhancing patient care and addressing the rising costs of biologic therapies."
Market Impact and Healthcare Economics
Both partnerships are specifically designed to address the rising costs of biologic therapies while enhancing patient access to advanced treatments. The agreements represent mAbxience's broader strategy to make biosimilar therapies more accessible across diverse geographic markets, potentially providing significant cost savings for healthcare systems.
Abiogen Pharma brings substantial commercial strength to the Italian partnership, with over €180 million in revenue as of 2023 and nearly 500 employees at the group level, ranking among the 15 largest Italian pharmaceutical companies. The company's expertise spans bone metabolism, pain treatment, respiratory, metabolic, and dermatological disorders, with a production facility exceeding 10,000 square meters.
The Southeast European partnership leverages Corapharm's specialized regional expertise and extensive network across multiple markets, positioning both companies to effectively navigate the complex regulatory and commercial landscape of the region.
Strategic Implications
These licensing agreements mark important milestones in mAbxience's global expansion strategy, demonstrating the company's commitment to making advanced biologic therapies more accessible worldwide. By partnering with established local companies that possess deep market knowledge and commercial infrastructure, mAbxience can efficiently enter new territories while maintaining focus on its core competency in biosimilar development and manufacturing.
Both partnerships expect to enhance patient access to advanced treatments while helping healthcare systems manage the economic burden of biologic therapies, potentially setting a model for future biosimilar market expansion strategies across Europe.
